
RGC
Healthcare · Drug Manufacturers - Specialty & Generic · $2.45B market cap
Next report
Time not confirmed
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jan 6, 2027 · upcoming | Time not confirmed | — | — | — |
| Oct 30, 2026 | Time not confirmed | — | — | — |
| Nov 18, 2025 | After the close | 0.00 | 0.00 | — |
| Jun 30, 2025 | Time not confirmed | — | 0.00 | — |
| Oct 25, 2024 | Time not confirmed | — | 0.00 | — |
| Oct 31, 2022 | After the close | 0.00 | -0.30 | — |
| Jun 2, 2022 | Time not confirmed | — | -0.29 | — |
| Oct 29, 2021 | Time not confirmed | — | -0.11 | — |
| Apr 26, 2021 | Time not confirmed | — | -33.38 | — |
| Mar 31, 2021 | Time not confirmed | 0.00 | -0.05 | — |
| Dec 31, 2020 | Time not confirmed | 0.00 | -0.02 | — |
| Sep 30, 2020 | Time not confirmed | 0.00 | -0.02 | — |
| Jun 30, 2020 | Time not confirmed | 0.00 | -0.03 | — |
| Mar 31, 2020 | Time not confirmed | 0.00 | -0.03 | — |
Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in…
| Dec 31, 2019 |
| Time not confirmed |
| 0.00 |
| -0.01 |
| — |
| Sep 30, 2019 | Time not confirmed | 0.00 | -0.01 | — |